AstraZeneca PLC (AZN)
AZNNYSEBiotechnology: Pharmaceutical Preparations
$186.27
-3.12 (-1.65%) today
Regular session, Nov 10, 1:25 PM ET
- Market cap
- $288.85bn
- P/E
- 20.6
- EPS, last 4 quarters
- $9.06
- Dividend yield
- –
- Day range
- $184.96 to $188.10
- 52-week range
- $153.41 to $212.71
- Average volume
- 6.00m
- Previous close
- $189.39
Analysts
14 coveringBuy12 buy, 2 hold, 0 sell
Targets a year out average $217.67, +16.9% from here
Earnings
next estimate $2.23Next report
Dec 2025
-51.4%
Mar 2026
+0.4%
Jun 2026
+5.2%
Sep 2026
+7.3%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- AstraZeneca Gains Single-Cell Bioconjugation Technology Through Omniose Deal RTTNews · 2 hours ago
- AstraZeneca Acquires Omniose Following Three-Year Research Collaboration RTTNews · 3 hours ago
- MRK's 2027 Outlook Challenging, Long-Term Prospects PromisingZacks · 1 day ago
- Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?Zacks · 4 days ago
- IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock UpZacks · 4 days ago
- JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent LossesZacks · 4 days ago
- MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?Zacks · 5 days ago
- SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in FocusZacks · 5 days ago
The company
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- Europe
- Website
- astrazeneca.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.